What is Conexeu?
Conexeu Sciences Inc. is at the forefront of regenerative medicine, developing innovative tissue solutions powered by its proprietary CXU Scaffold Technology. The company's flagship product, Ten-Minute-Tissue, is a revolutionary liquid skin substitute designed to rapidly gel within the body. This technology facilitates enhanced wound healing and significantly minimizes scarring, addressing critical needs in wound care for conditions such as burns and diabetic ulcers, as well as aesthetic applications. Originating from advanced cellular therapy research at the University of British Columbia, Conexeu Sciences is poised to transform both wound care and aesthetic treatment paradigms.
How much funding has Conexeu raised?
Conexeu has raised a total of $4M across 4 funding rounds:
Private Equity
$1.3M
Multiple Rounds
$2.7M
Private Equity (2025): $1.3M, investors not publicly disclosed
Private Equity (2026): $810K, investors not publicly disclosed
Private Equity (2026): $45K, investors not publicly disclosed
Private Equity (2026): $1.8M, investors not publicly disclosed
What's next for Conexeu?
With substantial enterprise-level backing and a recent strategic investment, Conexeu Sciences is well-positioned for accelerated growth and market penetration. The company's focus on its patented CXU Scaffold Technology and the commercialization of Ten-Minute-Tissue indicates a strategic push towards scaling operations and expanding its therapeutic applications. Future developments are likely to involve further clinical validation, broader market access, and potential partnerships to leverage its unique regenerative medicine platform.
See full Conexeu company page
